Sickle-cell disease future or investigational therapies

Sickle-cell disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Sickle-cell disease from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
History & Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Sickle-cell disease future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sickle-cell disease future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Sickle-cell disease future or investigational therapies
CDC on Sickle-cell disease future or investigational therapies
Sickle-cell disease future or investigational therapies in the news
Blogs onSickle-cell disease future or investigational therapies
Directions to Hospitals Treating Sickle-cell disease
Risk calculators and risk factors for Sickle-cell disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Future treatments

Various approaches are being sought for preventing sickling episodes as well as for the complications of sickle-cell disease. Other ways to modify Hb switching are being investigated, including the use of phytochemicals such as Nicosan.

Gene therapy is under investigation.